Candriam is one of leading European asset managers in sustainable and responsible investing with a growing footprint in North America and Asia. The company currently manages over $50 billion in ESG strategies offering one of the broadest ranges of ESG strategies and services across all asset classes and geographic regions. In addition, all its traditional equity, fixed income and asset allocation investments integrate ESG in their strategy and investment decisions making.

Candriam is fully committed to further expand its ESG capabilities. Candriam’s ESG team has a wide mandate and analyses corporate and country-based environmental, social and governance (ESG) opportunities and risks. Based on a rigorous and proprietary analysis framework, the ESG analysts scrutinize material sustainability information, ESG factors and trends that determine the eligibility & performance of companies (or countries) for Candriam’s ESG and ESG thematic funds. This research is distributed across Candriam allowing portfolio managers to integrate sustainability into all traditional investment processes.

Biotechnology companies are key enablers of scientific research and the development of new treatments for diseases such as cancer, infectious diseases, diabetes. This sector brings a specific set of challenges to the ESG analyst: governance structure of early-stage companies, potential societal impact of products in the pipeline, and availability of data.

The below described tasks are to be performed. The objective is to develop an ambitious biotechnology analysis framework and integrate relevant data in the management of our assets: 

1.ESG Analysis : Evaluate the ESG performance of Health Care companies with a focus on small biotechnology companies, leveraging Candriam’s internal ESG evaluation framework

2.Engagement : Organize meetings with issuers in portfolio to drive transparency and change on a range of ESG issues.

3.Assist in the development of an Impact measurement framework for Biotech and Healthcare companies  Devise a tool/analysis framework to assess how drug candidates and commercialized drugs benefit patients in developed and in LMIC countries.